Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLICROSS Trial
2024-518705-18-00Phase 4Authorised
- Sponsor
- Fundación Epic
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin + atorvastatin + ramipril in coronary arteriosclerosis, hyperlipidemia and hypertension (HTN) (2 arms), sponsored by Fundación Epic. Primary endpoints: Systolic blood pressure level and LDL cholesterol. Planned start Nov 2024; status: authorised.
02
Drugs
aspirin + atorvastatin + ramipril
03
Conditions
coronary arteriosclerosishyperlipidemiahypertension (HTN)
Beyond the preview
Go deeper on 2024-518705-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518705-18-00.